|
1
|
Deribe YL, Pawson T and Dikic I:
Post-translational modifications in signal integration. Nat Struct
Mol Biol. 17:666–672. 2010. View Article : Google Scholar
|
|
2
|
Flotho A and Melchior F: Sumoylation: A
regulatory protein modification in health and disease. Ann Rev
Biochem. 82:357–385. 2013. View Article : Google Scholar
|
|
3
|
Bergink S and Jentsch S: Principles of
ubiquitin and SUMO modifications in DNA repair. Nature.
458:461–467. 2009. View Article : Google Scholar
|
|
4
|
Iribarren PA, Di Marzio LA, Berazategui
MA, De Gaudenzi JG and Alvarez VE: SUMO polymeric chains are
involved in nuclear foci formation and chromatin organization in
Trypanosoma brucei procyclic forms. PLoS One. 13:e01935282018.
View Article : Google Scholar
|
|
5
|
Hendriks I, Lyon D, Young C, Jensen L,
Vertegaal A and Nielsen M: Site-specific mapping of the human SUMO
proteome reveals co-modification with phosphorylation. Nat Struct
Mol Biol. 24:325–336. 2017. View Article : Google Scholar
|
|
6
|
Hendriks I and Vertegaal A: A
comprehensive compilation of SUMO proteomics. Nat Rev Mol Cell
Biol. 17:581–595. 2016. View Article : Google Scholar
|
|
7
|
Beltrao P, Bork P, Krogan N and van Noort
V: Evolution and functional cross-talk of protein
post-translational modifications. Mol Syst Biol. 9:7142013.
View Article : Google Scholar
|
|
8
|
Zhao X: SUMO-mediated regulation of
nuclear functions and signaling processes. Mol Cell. 71:409–418.
2018. View Article : Google Scholar
|
|
9
|
Enserink JM: Sumo and the cellular stress
response. Cell Div. 10:42015. View Article : Google Scholar
|
|
10
|
Minguez P, Parca L, Diella F, Mende DR,
Kumar R, Helmer-Citterich M, Gavin AC, van Noort V and Bork P:
Deciphering a global network of functionally associated
post-translational modifications. Mol Syst Biol. 8:5992012.
View Article : Google Scholar
|
|
11
|
Han ZJ, Feng YH, Gu BH, Li YM and Chen H:
The post-translational modification, SUMOylation, and cancer
(Review). Int J Oncol. 52:1081–1094. 2018.
|
|
12
|
Mattoscio D and Chiocca S: SUMO pathway
components as possible cancer biomarkers. Future Oncol.
11:1599–1610. 2015. View Article : Google Scholar
|
|
13
|
Xie M, Yu J, Ge S, Huang J and Fan X:
SUMOylation homeostasis in tumorigenesis. Cancer Lett. 469:301–309.
2020. View Article : Google Scholar
|
|
14
|
Neuse CJ, Lomas OC, Schliemann C, Shen YJ,
Manier S, Bustoros M and Ghobrial IM: Genome instability in
multiple myeloma. Leukemia. 34:2887–2897. 2020. View Article : Google Scholar
|
|
15
|
Rajkumar SV and Kumar S: Multiple myeloma
current treatment algorithms. Blood Cancer J. 10:942020. View Article : Google Scholar
|
|
16
|
Sha Z and Goldberg AL: Multiple myeloma
cells are exceptionally sensitive to heat shock, which overwhelms
their proteostasis network and induces apoptosis. Proc Natl Acad
Sci USA. 117:21588–21597. 2020. View Article : Google Scholar
|
|
17
|
Zhao Q, Ma Y, Li Z, Zhang K, Zheng M and
Zhang S: The function of SUMOylation and its role in the
development of cancer cells under stress conditions: A systematic
review. Stem Cells Int. 2020:88357142020. View Article : Google Scholar
|
|
18
|
Li YY, Wang H, Yang XX, Geng HY, Gong G,
Kim HJ, Zhou YH and Wu JJ: Small Ubiquitin-Like Modifier 4 (SUMO4)
Gene M55V polymorphism and type 2 diabetes mellitus: A
Meta-analysis including 6,823 subjects. Front Endocrinol.
8:3032017. View Article : Google Scholar
|
|
19
|
Bohren KM, Nadkarni V, Song JH, Gabbay KH
and Owerbach D: A M55V polymorphism in a novel SUMO gene (SUMO-4)
differentially activates heat shock transcription factors and is
associated with susceptibility to type I diabetes mellitus. J Biol
Chem. 279:27233–27238. 2004. View Article : Google Scholar
|
|
20
|
Liang YC, Lee CC, Yao YL, Lai CC, Schmitz
ML and Yang WM: SUMO5, a Novel Poly-SUMO isoform, regulates PML
nuclear bodies. Sci Rep. 6:265092016. View Article : Google Scholar
|
|
21
|
Gong L, Li B, Millas S and Yeh ET:
Molecular cloning and characterization of human AOS1 and UBA2,
components of the sentrin-activating enzyme complex. FEBS Lett.
448:185–189. 1999. View Article : Google Scholar
|
|
22
|
Desterro JM, Rodriguez MS, Kemp GD and Hay
RT: Identification of the enzyme required for activation of the
small ubiquitin-like protein SUMO-1. J Biol Chem. 274:10618–10624.
1999. View Article : Google Scholar
|
|
23
|
Müller S, Hoege C, Pyrowolakis G and
Jentsch S: SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell
Biol. 2:202–210. 2001. View Article : Google Scholar
|
|
24
|
Johnson ES: Protein modification by SUMO.
Ann Rev Biochem. 73:355–382. 2004. View Article : Google Scholar
|
|
25
|
Tatham MH, Jaffray E, Vaughan OA, Desterro
JM, Botting CH, Naismith JH and Hay RT: Polymeric chains of SUMO-2
and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and
Ubc9. J Biol Chem. 276:35368–35374. 2001. View Article : Google Scholar
|
|
26
|
Sriramachandran AM, Meyer-Teschendorf K,
Pabst S, Ulrich HD, Gehring NH, Hofmann K, Praefcke GJ and Dohmen
RJ: Arkadia/RNF111 is a SUMO-targeted ubiquitin ligase with
preference for substrates marked with SUMO1-capped SUMO2/3 chain.
Nat Commun. 10:36782019. View Article : Google Scholar
|
|
27
|
Drag M and Salvesen GS: DeSUMOylating
enzymes-SENPs. IUBMB Life. 60:734–742. 2008. View Article : Google Scholar
|
|
28
|
Hecker CM, Rabiller M, Haglund K, Bayer P
and Dikic I: Specification of SUMO1- and SUMO2-interacting motifs.
J Biol Chem. 281:16117–16127. 2006. View Article : Google Scholar
|
|
29
|
Chen Y, Sun XX, Sears RC and Dai MS:
Writing and erasing MYC ubiquitination and SUMOylation. Genes Dis.
6:359–371. 2019. View Article : Google Scholar
|
|
30
|
Fan L, Bi T, Wang L and Xiao W: DNA-damage
tolerance through PCNA ubiquitination and sumoylation. Biochem J.
477:2655–2677. 2020. View Article : Google Scholar
|
|
31
|
Sriramachandran AM and Dohmen RJ:
SUMO-targeted ubiquitin ligases. Biochim Biophys Acta. 1843:75–85.
2014. View Article : Google Scholar
|
|
32
|
Johnson ES, Schwienhorst I, Dohmen RJ and
Blobel G: The ubiquitin-like protein Smt3p is activated for
conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO
J. 16:5509–5519. 1997. View Article : Google Scholar
|
|
33
|
Lois LM and Lima CD: Structures of the
SUMO E1 provide mechanistic insights into SUMO activation and E2
recruitment to E1. EMBO J. 24:439–451. 2005. View Article : Google Scholar
|
|
34
|
Cappadocia L, Pichler A and Lima CD:
Structural basis for catalytic activation by the human ZNF451 SUMO
E3 ligase. Nat Struct Mol Biol. 22:968–975. 2015. View Article : Google Scholar
|
|
35
|
Eisenhardt N, Chaugule VK, Koidl S,
Droescher M, Dogan E, Rettich J, Sutinen P, Imanishi SY, Hofmann K,
Palvimo JJ and Pichler A: A new vertebrate SUMO enzyme family
reveals insights into SUMO-chain assembly. Nat Struct Mol Biol.
22:959–967. 2015. View Article : Google Scholar
|
|
36
|
Werner A, Flotho A and Melchior F: The
RanBP2/RanGAP1*SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase.
Mol Cell. 46:287–298. 2012. View Article : Google Scholar
|
|
37
|
Drabikowski K: Ubiquitin and SUMO
Modifications in Caenorhabditis elegans stress response. Curr
Issues Mol Biol. 35:145–158. 2020. View Article : Google Scholar
|
|
38
|
Lu W, Wang Q, Xu C, Yuan H, Fan Q, Chen B,
Cai R, Wu D and Xu M: SUMOylation is essential for Sirt2
tumor-suppressor function in neuroblastoma. Neoplasia. 23:129–139.
2021. View Article : Google Scholar
|
|
39
|
Chanda A, Sarkar A and Bonni S: The SUMO
System and TGFβ signaling interplay in regulation of
epithelial-mesenchymal transition: Implications for cancer
progression. Cancers (Basel). 10:2642018. View Article : Google Scholar
|
|
40
|
Wu G, Xu Y, Ruan N, Li J, Lv Q, Zhang Q,
Chen Y, Wang Q, Xia Q and Li Q: Genetic alteration and clinical
significance of SUMOylation regulators in multiple cancer types. J
Cancer. 11:6823–6833. 2020. View Article : Google Scholar
|
|
41
|
Boulanger M, Paolillo R, Piechaczyk M and
Bossis G: The SUMO pathway in Hematomalignancies and their response
to therapies. Int J Mol Sci. 20:38952019. View Article : Google Scholar
|
|
42
|
Küppers R: Mechanisms of B-cell lymphoma
pathogenesis. Nat Rev Cancer. 5:251–262. 2005. View Article : Google Scholar
|
|
43
|
Driscoll JJ, Pelluru D, Lefkimmiatis K,
Fulciniti M, Prabhala RH, Greipp PR, Barlogie B, Tai YT, Anderson
KC, Shaughnessy JD Jr, et al: The sumoylation pathway is
dysregulated in multiple myeloma and is associated with adverse
patient outcome. Blood. 115:2827–2834. 2010. View Article : Google Scholar
|
|
44
|
Chen YC, Hsu WL, Ma YL, Tai DJ and Lee EH:
CREB SUMOylation by the E3 ligase PIAS1 enhances spatial memory. J
Neurosci. 34:9574–9589. 2014. View Article : Google Scholar
|
|
45
|
Hoellein A, Fallahi M, Schoeffmann S,
Steidle S, Schaub FX, Rudelius M, Laitinen I, Nilsson L, Goga A,
Peschel C, et al: Myc-induced SUMOylation is a therapeutic
vulnerability for B-cell lymphoma. Blood. 124:2081–2090. 2014.
View Article : Google Scholar
|
|
46
|
Jiang B, Fan X, Zhang D, Liu H and Fan C:
Identifying UBA2 as a proliferation and cell cycle regulator in
lung cancer A549 cells. J Cell Biochem. 120:12752–12761. 2019.
View Article : Google Scholar
|
|
47
|
Licciardello MP, Müllner MK, Dürnberger G,
Kerzendorfer C, Boidol B, Trefzer C, Sdelci S, Berg T, Penz T,
Schuster M, et al: NOTCH1 activation in breast cancer confers
sensitivity to inhibition of SUMOylation. Oncogene. 34:3780–3790.
2015. View Article : Google Scholar
|
|
48
|
Yan S, Li A and Liu Y: CacyBP/SIP inhibits
the migration and invasion behaviors of glioblastoma cells through
activating Siah1 mediated ubiquitination and degradation of
cytoplasmic p27. Cell Biol Int. 42:216–226. 2018. View Article : Google Scholar
|
|
49
|
Imamura Y, Wang PL, Masuno K and Sogawa N:
Salivary protein histatin 3 regulates cell proliferation by
enhancing p27(Kip1) and heat shock cognate protein 70
ubiquitination. Biochem Biophys Res Commun. 470:269–274. 2016.
View Article : Google Scholar
|
|
50
|
Wang L, Bai G and Chen F: Human bone
marrow mesenchymal stem cells suppress the proliferation of hepatic
stellate cells by inhibiting the ubiquitination of p27. Biochem
Cell Biol. 95:628–633. 2017. View Article : Google Scholar
|
|
51
|
Huang X, Tao Y, Gao J, Zhou X, Tang S,
Deng C, Lai Z, Lin X, Wang Q and Li T: UBC9 coordinates
inflammation affecting development of bladder cancer. Sci Rep.
10:206702020. View Article : Google Scholar
|
|
52
|
He W, Verhees GF, Bhagwat N, Yang Y,
Kulkarni DS, Lombardo Z, Lahiri S, Roy P, Zhuo J, Dang B, et al:
SUMO fosters assembly and functionality of the MutSγ complex to
facilitate meiotic crossing over. Dev Cell. 56:2073–2088.e3. 2021.
View Article : Google Scholar
|
|
53
|
Kaul S, Blackford JA Jr, Cho S and Simons
SS Jr: Ubc9 is a novel modulator of the induction properties of
glucocorticoid receptors. J Biol Chem. 277:12541–12549. 2002.
View Article : Google Scholar
|
|
54
|
Chakrabarti SR, Sood R, Ganguly S,
Bohlander S, Shen Z and Nucifora G: Modulation of TEL transcription
activity by interaction with the ubiquitin-conjugating enzyme UBC9.
Proc Natl Acad Sci USA. 96:7467–7472. 1999. View Article : Google Scholar
|
|
55
|
Zhu S, Sachdeva M, Wu F, Lu Z and Mo YY:
Ubc9 promotes breast cell invasion and metastasis in a
sumoylation-independent manner. Oncogene. 29:1763–1772. 2010.
View Article : Google Scholar
|
|
56
|
Li C, McManus FP, Plutoni C, Pascariu CM,
Nelson T, Alberici Delsin LE, Emery G and Thibault P: Quantitative
SUMO proteomics identifies PIAS1 substrates involved in cell
migration and motility. Nat Commun. 11:8342020. View Article : Google Scholar
|
|
57
|
Liu B, Tahk S, Yee KM, Fan G and Shuai K:
The ligase PIAS1 restricts natural regulatory T cell
differentiation by epigenetic repression. Science. 330:521–525.
2010. View Article : Google Scholar
|
|
58
|
Kotaja N, Vihinen M, Palvimo JJ and Jänne
OA: Androgen receptor-interacting protein 3 and other PIAS proteins
cooperate with glucocorticoid receptor-interacting protein 1 in
steroid receptor-dependent signaling. J Biol Chem. 277:17781–17788.
2002. View Article : Google Scholar
|
|
59
|
Galanty Y, Belotserkovskaya R, Coates J,
Polo S, Miller KM and Jackson SP: Mammalian SUMO E3-ligases PIAS1
and PIAS4 promote responses to DNA double-strand breaks. Nature.
462:935–939. 2009. View Article : Google Scholar
|
|
60
|
Hoefer J, Schäfer G, Klocker H, Erb HH,
Mills IG, Hengst L, Puhr M and Culig Z: PIAS1 is increased in human
prostate cancer and enhances proliferation through inhibition of
p21. Am J Pathol. 180:2097–2107. 2012. View Article : Google Scholar
|
|
61
|
Rabellino A, Melegari M, Tompkins VS, Chen
W, Van Ness BG, Teruya-Feldstein J, Conacci-Sorrell M, Janz S and
Scaglioni PP: PIAS1 promotes Lymphomagenesis through MYC
upregulation. Cell Rep. 15:2266–2278. 2016. View Article : Google Scholar
|
|
62
|
Kadaré G, Toutant M, Formstecher E, Corvol
JC, Carnaud M, Boutterin MC and Girault JA: PIAS1-mediated
sumoylation of focal adhesion kinase activates its
autophosphorylation. J Biol Chem. 278:47434–47440. 2003. View Article : Google Scholar
|
|
63
|
Rabellino A, Carter B, Konstantinidou G,
Wu SY, Rimessi A, Byers LA, Heymach JV, Girard L, Chiang CM,
Teruya-Feldstein J and Scaglioni PP: The SUMO E3-ligase PIAS1
regulates the tumor suppressor PML and its oncogenic counterpart
PML-RARA. Cancer Res. 72:2275–2284. 2012. View Article : Google Scholar
|
|
64
|
Schmidt D and Müller S: Members of the
PIAS family act as SUMO ligases for c-Jun and p53 and repress p53
activity. Proc Natl Acad Sci USA. 99:2872–2877. 2002. View Article : Google Scholar
|
|
65
|
Moreno-Oñate M, Herrero-Ruiz AM,
García-Dominguez M, Cortés-Ledesma F and Ruiz JF: RanBP2-mediated
SUMOylation promotes human DNA polymerase lambda nuclear
localization and DNA repair. J Mol Biol. 432:3965–3979. 2020.
View Article : Google Scholar
|
|
66
|
Wang H, Luo Q, Kang J, Wei Q, Yang Y, Yang
D, Liu X, Liu T and Yi P: YTHDF1 aggravates the progression of
cervical cancer through m6A-mediated up-regulation of
RANBP2. Front Oncol. 11:6503832021. View Article : Google Scholar
|
|
67
|
Gilistro E, de Turris V, Damizia M,
Verrico A, Moroni S, De Santis R, Rosa A and Lavia P: Importin-β
and CRM1 control a RANBP2 spatiotemporal switch essential for
mitotic kinetochore function. J Cell Sci. 130:2564–2578. 2017.
|
|
68
|
Maarifi G, Fernandez J, Portilho DM,
Boulay A, Dutrieux J, Oddos S, Butler-Browne G, Nisole S and Arhel
NJ: RanBP2 regulates the anti-retroviral activity of TRIM5α by
SUMOylation at a predicted phosphorylated SUMOylation motif. Commun
Biol. 1:1932018. View Article : Google Scholar
|
|
69
|
Kunz K, Piller T and Müller S:
SUMO-specific proteases and isopeptidases of the SENP family at a
glance. J Cell Sci. 131:jcs2119042018. View Article : Google Scholar
|
|
70
|
Chauhan KM, Chen Y, Chen Y, Liu AT, Sun XX
and Dai MS: The SUMO-specific protease SENP1 deSUMOylates p53 and
regulates its activity. J Cell Biochem. 122:189–197. 2021.
View Article : Google Scholar
|
|
71
|
Bawa-Khalfe T, Yang FM, Ritho J, Lin HK,
Cheng J and Yeh ET: SENP1 regulates PTEN stability to dictate
prostate cancer development. Oncotarget. 8:17651–17664. 2017.
View Article : Google Scholar
|
|
72
|
Song MS, Salmena L, Carracedo A, Egia A,
Lo-Coco F, Teruya-Feldstein J and Pandolfi PP: The
deubiquitinylation and localization of PTEN are regulated by a
HAUSP-PML network. Nature. 455:813–817. 2008. View Article : Google Scholar
|
|
73
|
Sun XX, Chen Y, Su Y, Wang X, Chauhan KM,
Liang J, Daniel CJ, Sears RC and Dai MS: SUMO protease SENP1
deSUMOylates and stabilizes c-Myc. Proc Natl Acad Sci USA.
115:10983–10988. 2018. View Article : Google Scholar
|
|
74
|
Huang X, Zuo Y, Wang X, Wu X, Tan H, Fan
Q, Dong B, Xue W, Chen GQ and Cheng J: SUMO-specific protease 1 is
critical for myeloid-derived suppressor cell development and
function. Cancer Res. 79:3891–3902. 2019. View Article : Google Scholar
|
|
75
|
Kanapathipillai M: Treating p53 mutant
aggregation-associated cancer. Cancers (Basel). 10:1542018.
View Article : Google Scholar
|
|
76
|
Carter S, Bischof O, Dejean A and Vousden
KH: C-terminal modifications regulate MDM2 dissociation and nuclear
export of p53. Nat Cell Biol. 9:428–435. 2007. View Article : Google Scholar
|
|
77
|
Wu SY and Chiang CM: Crosstalk between
sumoylation and acetylation regulates p53-dependent chromatin
transcription and DNA binding. EMBO J. 28:1246–1259. 2009.
View Article : Google Scholar
|
|
78
|
Ding B, Sun Y and Huang J: Overexpression
of SKI oncoprotein leads to p53 degradation through regulation of
MDM2 protein sumoylation. J Biol Chem. 287:14621–14630. 2012.
View Article : Google Scholar
|
|
79
|
Deng C, Lipstein MR, Scotto L, Jirau
Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX, et
al: Silencing c-Myc translation as a therapeutic strategy through
targeting PI3Kδ and CK1ε in hematological malignancies. Blood.
129:88–99. 2017. View Article : Google Scholar
|
|
80
|
Amente S, Lavadera ML, Palo GD and Majello
B: SUMOactivating SAE1 transcription is positively regulated by
Myc. Am J Cancer Res. 2:330–334. 2012.
|
|
81
|
Kessler JD, Kahle KT, Sun T, Meerbrey KL,
Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, et
al: A SUMOylation-dependent transcriptional subprogram is required
for Myc-driven tumorigenesis. Science. 335:348–353. 2012.
View Article : Google Scholar
|
|
82
|
Wang WH, Yuan T, Qian MJ, Yan FJ, Yang L,
He JQ, Yang B, Lu JJ and Zhu H: Post-translational modification of
KRAS: Potential targets for cancer therapy. Acta Pharmacol Sin.
42:1201–1211. 2021. View Article : Google Scholar
|
|
83
|
Uprety D and Adjei AA: KRAS: From
undruggable to a druggable Cancer Target. Cancer Treat Rev.
89:1020702020. View Article : Google Scholar
|
|
84
|
Moutty MC, Sakin V and Melchior F:
Importin α/β mediates nuclear import of individual SUMO E1 subunits
and of the holo-enzyme. Mol Biol Cell. 22:652–660. 2011. View Article : Google Scholar
|
|
85
|
Choi BH, Philips MR, Chen Y, Lu L and Dai
W: K-Ras Lys-42 is crucial for its signaling, cell migration, and
invasion. J Biol Chem. 293:17574–17581. 2018. View Article : Google Scholar
|
|
86
|
Boddy MN, Howe K, Etkin LD, Solomon E and
Freemont PS: PIC 1, a novel ubiquitin-like protein which interacts
with the PML component of a multiprotein complex that is disrupted
in acute promyelocytic leukaemia. Oncogene. 13:971–982. 1996.
|
|
87
|
de Thé H, Pandolfi PP and Chen Z: Acute
promyelocytic leukemia: A paradigm for oncoprotein-targeted cure.
Cancer Cell. 32:552–560. 2017. View Article : Google Scholar
|
|
88
|
Rao Y, Li R and Zhang D: A drug from
poison: How the therapeutic effect of arsenic trioxide on acute
promyelocytic leukemia was discovered. Sci China Life Sci.
56:495–502. 2013. View Article : Google Scholar
|
|
89
|
Zhu J, Zhou J, Peres L, Riaucoux F, Honoré
N, Kogan S and de Thé H: A sumoylation site in PML/RARA is
essential for leukemic transformation. Cancer Cell. 7:143–153.
2005. View Article : Google Scholar
|
|
90
|
Stubbe M, Mai J, Paulus C, Stubbe HC,
Berscheminski J, Karimi M, Hofmann S, Weber E, Hadian K, Hay R, et
al: Viral DNA binding protein SUMOylation promotes PML nuclear body
localization next to viral replication centers. mBio. 11:e00049–20.
2020. View Article : Google Scholar
|
|
91
|
El-Asmi F, El-Mchichi B, Maroui MA,
Dianoux L and Chelbi-Alix MK: TGF-β induces PML SUMOylation,
degradation and PML nuclear body disruption. Cytokine. 120:264–272.
2019. View Article : Google Scholar
|
|
92
|
Sahin U, Ferhi O, Jeanne M, Benhenda S,
Berthier C, Jollivet F, Niwa-Kawakita M, Faklaris O, Setterblad N,
de Thé H and Lallemand-Breitenbach V: Oxidative stress-induced
assembly of PML nuclear bodies controls sumoylation of partner
proteins. J Cell Biol. 204:931–945. 2014. View Article : Google Scholar
|
|
93
|
Li Y, Ma X, Wu W, Chen Z and Meng G: PML
nuclear body biogenesis, carcinogenesis, and targeted therapy.
Trends Cancer. 6:889–906. 2020. View Article : Google Scholar
|
|
94
|
Ben-Porath I and Weinberg RA: The signals
and pathways activating cellular senescence. Int J Biochem Cell
Biol. 37:961–976. 2005. View Article : Google Scholar
|
|
95
|
Morris EJ and Dyson NJ: Retinoblastoma
protein partners. Adv Cancer Res. 82:1–54. 2001. View Article : Google Scholar
|
|
96
|
Lee BY, Han JA, Im JS, Morrone A, Johung
K, Goodwin EC, Kleijer WJ, DiMaio D and Hwang ES:
Senescence-associated beta-galactosidase is lysosomal
beta-galactosidase. Aging Cell. 5:187–195. 2006. View Article : Google Scholar
|
|
97
|
Trimarchi JM and Lees JA: Sibling rivalry
in the E2F family. Nat Rev Mol Cell Biol. 3:11–20. 2002. View Article : Google Scholar
|
|
98
|
Bischof O, Schwamborn K, Martin N, Werner
A, Sustmann C, Grosschedl R and Dejean A: The E3 SUMO ligase PIASy
is a regulator of cellular senescence and apoptosis. Mol Cell.
22:783–794. 2006. View Article : Google Scholar
|
|
99
|
Yu B, Swatkoski S, Holly A, Lee LC, Giroux
V, Lee CS, Hsu D, Smith JL, Yuen G, Yue J, et al: Oncogenesis
driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9.
Proc Natl Acad Sci USA. 112:E1724–E1733. 2015. View Article : Google Scholar
|
|
100
|
Luo J, Emanuele MJ, Li D, Creighton CJ,
Schlabach MR, Westbrook TF, Wong KK and Elledge SJ: A genome-wide
RNAi screen identifies multiple synthetic lethal interactions with
the Ras oncogene. Cell. 137:835–848. 2009. View Article : Google Scholar
|
|
101
|
Gallipoli P and Huntly BJP: Novel
epigenetic therapies in hematological malignancies: Current status
and beyond. Semin Cancer Biol. 51:198–210. 2018. View Article : Google Scholar
|
|
102
|
Bryder D, Rossi DJ and Weissman IL:
Hematopoietic stem cells: The paradigmatic tissue-specific stem
cell. Am J Pathol. 169:338–346. 2006. View Article : Google Scholar
|
|
103
|
Tempé D, Piechaczyk M and Bossis G: SUMO
under stress. Biochem Soc Trans. 36:874–878. 2008. View Article : Google Scholar
|
|
104
|
Rajkumar SV: Multiple myeloma. Curr Probl
Cancer. 33:7–64. 2009. View Article : Google Scholar
|
|
105
|
Röllig C, Knop S and Bornhäuser M:
Multiple myeloma. Lancet. 385:2197–2208. 2015. View Article : Google Scholar
|
|
106
|
Susanibar Adaniya SP, Cohen AD and Garfall
AL: Chimeric antigen receptor T cell immunotherapy for multiple
myeloma: A review of current data and potential clinical
applications. Am J Hematol. 94(Suppl 1): S28–S33. 2019. View Article : Google Scholar
|
|
107
|
Atrash S, Bano K, Harrison B and Abdallah
AO: CAR-T treatment for hematological malignancies. J Investig Med.
68:956–964. 2020. View Article : Google Scholar
|
|
108
|
Gagelmann N, Riecken K, Wolschke C, Berger
C, Ayuk FA, Fehse B and Kröger N: Development of CAR-T cell
therapies for multiple myeloma. Leukemia. 34:2317–2332. 2020.
View Article : Google Scholar
|
|
109
|
Feng D and Sun J: Overview of anti-BCMA
CAR-T immunotherapy for multiple myeloma and relapsed/refractory
multiple myeloma. Scand J Immunol. 92:e129102020. View Article : Google Scholar
|
|
110
|
Minnie SA and Hill GR: Immunotherapy of
multiple myeloma. J Clin Invest. 130:1565–1575. 2020. View Article : Google Scholar
|
|
111
|
Xu J, Sun HY, Xiao FJ, Wang H, Yang Y,
Wang L, Gao CJ, Guo ZK, Wu CT and Wang LS: SENP1 inhibition induces
apoptosis and growth arrest of multiple myeloma cells through
modulation of NF-κB signaling. Biochem Biophys Res Commun.
460:409–415. 2015. View Article : Google Scholar
|
|
112
|
Xie H, Gu Y, Wang W, Wang X, Ye X, Xin C,
Lu M, Reddy BA and Shu P: Silencing of SENP2 in multiple myeloma
induces bortezomib resistance by activating NF-κB through the
modulation of IκBα sumoylation. Sci Rep. 10:7662020. View Article : Google Scholar
|
|
113
|
Tanaka K and Hirota T: Chromosomal
instability: A common feature and a therapeutic target of cancer.
Biochim Biophys Acta. 1866:64–75. 2016.
|
|
114
|
McGranahan N, Burrell RA, Endesfelder D,
Novelli MR and Swanton C: Cancer chromosomal instability:
Therapeutic and diagnostic challenges. EMBO Rep. 13:528–538. 2012.
View Article : Google Scholar
|
|
115
|
Giam M and Rancati G: Aneuploidy and
chromosomal instability in cancer: A jackpot to chaos. Cell Div.
10:32015. View Article : Google Scholar
|
|
116
|
Dantuma NP and van Attikum H:
Spatiotemporal regulation of posttranslational modifications in the
DNA damage response. EMBO J. 35:6–23. 2016. View Article : Google Scholar
|
|
117
|
Galanty Y, Belotserkovskaya R, Coates J
and Jackson SP: RNF4, a SUMO-targeted ubiquitin E3 ligase, promotes
DNA double-strand break repair. Genes Dev. 26:1179–1195. 2012.
View Article : Google Scholar
|
|
118
|
Biggins S, Bhalla N, Chang A, Smith DL and
Murray AW: Genes involved in sister chromatid separation and
segregation in the budding yeast Saccharomyces cerevisiae.
Genetics. 159:453–470. 2001. View Article : Google Scholar
|
|
119
|
Ohta S, Bukowski-Wills JC, Sanchez-Pulido
L, Alves Fde L, Wood L, Chen ZA, Platani M, Fischer L, Hudson DF,
Ponting CP, et al: The protein composition of mitotic chromosomes
determined using multiclassifier combinatorial proteomics. Cell.
142:810–821. 2010. View Article : Google Scholar
|
|
120
|
Thomas GE, Renjith MR and Manna TK:
Kinetochore-microtubule interactions in chromosome segregation:
Lessons from yeast and mammalian cells. Biochem J. 474:3559–3577.
2017. View Article : Google Scholar
|
|
121
|
Verdaasdonk JS and Bloom K: Centromeres:
Unique chromatin structures that drive chromosome segregation. Nat
Rev Mol Cell Biol. 12:320–332. 2011. View Article : Google Scholar
|
|
122
|
Eifler K, Cuijpers SAG, Willemstein E,
Raaijmakers JA, El Atmioui D, Ovaa H, Medema RH and Vertegaal AC:
SUMO targets the APC/C to regulate transition from metaphase to
anaphase. Nat Commun. 9:11192018. View Article : Google Scholar
|
|
123
|
Azuma Y, Arnaoutov A, Anan T and Dasso M:
PIASy mediates SUMO-2 conjugation of Topoisomerase-II on mitotic
chromosomes. EMBO J. 24:2172–2182. 2005. View Article : Google Scholar
|
|
124
|
Dawlaty MM, Malureanu L, Jeganathan KB,
Kao E, Sustmann C, Tahk S, Shuai K, Grosschedl R and van Deursen
JM: Resolution of sister centromeres requires RanBP2-mediated
SUMOylation of topoisomerase IIalpha. Cell. 133:103–115. 2008.
View Article : Google Scholar
|
|
125
|
Joseph J, Liu ST, Jablonski SA, Yen TJ and
Dasso M: The RanGAP1-RanBP2 complex is essential for
microtubule-kinetochore interactions in vivo. Curr Biol.
14:611–617. 2004. View Article : Google Scholar
|
|
126
|
Maison C, Romeo K, Bailly D, Dubarry M,
Quivy JP and Almouzni G: The SUMO protease SENP7 is a critical
component to ensure HP1 enrichment at pericentric heterochromatin.
Nat Struct Mol Biol. 19:458–460. 2012. View Article : Google Scholar
|
|
127
|
Eifler K and Vertegaal ACO:
SUMOylation-mediated regulation of cell cycle progression and
cancer. Trends Biochem Sci. 40:779–793. 2015. View Article : Google Scholar
|
|
128
|
Schimmel J, Eifler K, Sigurðsson JO,
Cuijpers SA, Hendriks IA, Verlaan-de Vries M, Kelstrup CD,
Francavilla C, Medema RH, Olsen JV and Vertegaal AC: Uncovering
SUMOylation dynamics during cell-cycle progression reveals FoxM1 as
a key mitotic SUMO target protein. Mol Cell. 53:1053–1066. 2014.
View Article : Google Scholar
|
|
129
|
Neyret-Kahn H, Benhamed M, Ye T, Le Gras
S, Cossec JC, Lapaquette P, Bischof O, Ouspenskaia M, Dasso M,
Seeler J, et al: Sumoylation at chromatin governs coordinated
repression of a transcriptional program essential for cell growth
and proliferation. Genome Res. 23:1563–1579. 2013. View Article : Google Scholar
|
|
130
|
Nacerddine K, Lehembre F, Bhaumik M, Artus
J, Cohen-Tannoudji M, Babinet C, Pandolfi PP and Dejean A: The SUMO
pathway is essential for nuclear integrity and chromosome
segregation in mice. Dev Cell. 9:769–779. 2005. View Article : Google Scholar
|
|
131
|
Bellail AC, Olson JJ and Hao C: SUMO1
modification stabilizes CDK6 protein and drives the cell cycle and
glioblastoma progression. Nat Commun. 5:42342014. View Article : Google Scholar
|
|
132
|
Guo Z, Kanjanapangka J, Liu N, Liu S, Liu
C, Wu Z, Wang Y, Loh T, Kowolik C, Jamsen J, et al: Sequential
posttranslational modifications program FEN1 degradation during
cell-cycle progression. Mol Cell. 47:444–456. 2012. View Article : Google Scholar
|
|
133
|
Cheng J, Wang D, Wang Z and Yeh ET: SENP1
enhances androgen receptor-dependent transcription through
desumoylation of histone deacetylase 1. Mol Cell Biol.
24:6021–6028. 2004. View Article : Google Scholar
|
|
134
|
Childs BG, Baker DJ, Kirkland JL, Campisi
J and van Deursen JM: Senescence and apoptosis: Dueling or
complementary cell fates? EMBO Rep. 15:1139–1153. 2014. View Article : Google Scholar
|
|
135
|
Lujambio A, Akkari L, Simon J, Grace D,
Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce JA,
Krizhanovsky V and Lowe SW: Non-cell-autonomous tumor suppression
by p53. Cell. 153:449–460. 2013. View Article : Google Scholar
|
|
136
|
Ivanschitz L, Takahashi Y, Jollivet F,
Ayrault O, Le Bras M and de Thé H: PML IV/ARF interaction enhances
p53 SUMO-1 conjugation, activation, and senescence. Proc Natl Acad
Sci USA. 112:14278–14283. 2015. View Article : Google Scholar
|
|
137
|
Yates KE, Korbel GA, Shtutman M, Roninson
IB and DiMaio D: Repression of the SUMO-specific protease Senp1
induces p53-dependent premature senescence in normal human
fibroblasts. Aging Cell. 7:609–621. 2008. View Article : Google Scholar
|
|
138
|
Lowe SW and Lin AW: Apoptosis in cancer.
Carcinogenesis. 21:485–495. 2000. View Article : Google Scholar
|
|
139
|
Kaufmann SH and Hengartner MO: Programmed
cell death: Alive and well in the new millennium. Trends Cell Biol.
11:526–534. 2001. View Article : Google Scholar
|
|
140
|
Zapata JM, Pawlowski K, Haas E, Ware CF,
Godzik A and Reed JC: A diverse family of proteins containing tumor
necrosis factor receptor-associated factor domains. J Biol Chem.
276:24242–24252. 2001. View Article : Google Scholar
|
|
141
|
Hockenbery D, Nuñez G, Milliman C,
Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial
membrane protein that blocks programmed cell death. Nature.
348:334–336. 1990. View Article : Google Scholar
|
|
142
|
Zamaraev AV, Kopeina GS, Prokhorova EA,
Zhivotovsky B and Lavrik IN: Post-translational modification of
Caspases: The other side of apoptosis regulation. Trends Cell Biol.
27:322–339. 2017. View Article : Google Scholar
|
|
143
|
Park JH, Lee SW, Yang SW, Yoo HM, Park JM,
Seong MW, Ka SH, Oh KH, Jeon YJ and Chung CH: Modification of DBC1
by SUMO2/3 is crucial for p53-mediated apoptosis in response to DNA
damage. Nat Commun. 5:54832014. View Article : Google Scholar
|
|
144
|
Xia W, Tian H, Cai X, Kong H, Fu W, Xing
W, Wang Y, Zou M, Hu Y and Xu D: Inhibition of SUMO-specific
protease 1 induces apoptosis of astroglioma cells by regulating
NF-κB/Akt pathways. Gene. 595:175–179. 2016. View Article : Google Scholar
|
|
145
|
Jiang Z, Fan Q, Zhang Z, Zou Y, Cai R,
Wang Q, Zuo Y and Cheng J: SENP1 deficiency promotes ER
stress-induced apoptosis by increasing XBP1 SUMOylation. Cell
Cycle. 11:1118–1122. 2012. View Article : Google Scholar
|
|
146
|
He X, Riceberg J, Pulukuri SM, Grossman S,
Shinde V, Shah P, Brownell JE, Dick L, Newcomb J and Bence N:
Characterization of the loss of SUMO pathway function on cancer
cells and tumor proliferation. PLoS One. 10. pp. e01238822015,
View Article : Google Scholar
|
|
147
|
Zhang M, Jiang D, Xie X, He Y, Lv M and
Jiang X: miR-129-3p inhibits NHEJ pathway by targeting SAE1 and
represses gastric cancer progression. Int J Clin Exp Pathol.
12:1539–1547. 2019.
|
|
148
|
Kalamarz ME, Paddibhatla I, Nadar C and
Govind S: Sumoylation is tumor-suppressive and confers
proliferative quiescence to hematopoietic progenitors in Drosophila
melanogaster larvae. Biol Open. 1:161–172. 2012. View Article : Google Scholar
|
|
149
|
Li S, Wang J, Hu G, Aman S, Li B, Li Y,
Xia K, Yang Y, Ahmad B, Wang M and Wu H: SUMOylation of MCL1
protein enhances its stability by regulating the
ubiquitin-proteasome pathway. Cell Signal. 73:1096862020.
View Article : Google Scholar
|
|
150
|
Chang CC, Naik MT, Huang YS, Jeng JC, Liao
PH, Kuo HY, Ho CC, Hsieh YL, Lin CH, Huang NJ, et al: Structural
and functional roles of Daxx SIM phosphorylation in SUMO
paralog-selective binding and apoptosis modulation. Mol Cell.
42:62–74. 2011. View Article : Google Scholar
|
|
151
|
Santiago A, Godsey AC, Hossain J, Zhao LY
and Liao D: Identification of two independent SUMO-interacting
motifs in Daxx: Evolutionary conservation from Drosophila to humans
and their biochemical functions. Cell Cycle. 8:76–87. 2009.
View Article : Google Scholar
|
|
152
|
Wasiak S, Zunino R and McBride HM: Bax/Bak
promote sumoylation of DRP1 and its stable association with
mitochondria during apoptotic cell death. J Cell Biol. 177:439–450.
2007. View Article : Google Scholar
|
|
153
|
Li P, Jing H, Wang Y, Yuan L, Xiao H and
Zheng Q: SUMO modification in apoptosis. J Mol Histol. 52:1–10.
2021. View Article : Google Scholar
|
|
154
|
Menon MB and Dhamija S: Beclin 1
Phosphorylation-at the center of autophagy regulation. Front Cell
Dev Biol. 6:1372018. View Article : Google Scholar
|
|
155
|
Sun J, Tai S, Tang L, Yang H, Chen M, Xiao
Y, Li X, Zhu Z and Zhou S: Acetylation modification during
autophagy and vascular aging. Front Physiol. 12:5982672021.
View Article : Google Scholar
|
|
156
|
Son SM, Park SJ, Fernandez-Estevez M and
Rubinsztein DC: Autophagy regulation by acetylation-implications
for neurodegenerative diseases. Exp Mol Med. 53:30–41. 2021.
View Article : Google Scholar
|
|
157
|
Wang R and Wang G: Protein modification
and autophagy activation. Adv Exp Med Biol. 1206:237–259. 2019.
View Article : Google Scholar
|
|
158
|
Hu B, Zhang Y, Deng T, Gu J, Liu J, Yang
H, Xu Y, Yan Y, Yang F, Zhang H, et al: PDPK1 regulates
autophagosome biogenesis by binding to PIK3C3. Autophagy. Sep
10–2020.Epub ahead of print. View Article : Google Scholar
|
|
159
|
Liu K, Guo C, Lao Y, Yang J, Chen F, Zhao
Y, Yang Y, Yang J and Yi J: A fine-tuning mechanism underlying
self-control for autophagy: DeSUMOylation of BECN1 by SENP3.
Autophagy. 16:975–990. 2020. View Article : Google Scholar
|
|
160
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar
|
|
161
|
Morrison CD, Parvani JG and Schiemann WP:
The relevance of the TGF-β Paradox to EMT-MET programs. Cancer
Lett. 341:30–40. 2013. View Article : Google Scholar
|
|
162
|
Lin X, Wang Y, Jiang Y, Xu M, Pang Q, Sun
J, Yu Y, Shen Z, Lei R and Xu J: Sumoylation enhances the activity
of the TGF-β/SMAD and HIF-1 signaling pathways in keloids. Life
Sci. 255:1178592020. View Article : Google Scholar
|
|
163
|
Xu R, Yu S, Zhu D, Huang X, Xu Y, Lao Y,
Tian Y, Zhang J, Tang Z, Zhang Z, et al: hCINAP regulates the
DNA-damage response and mediates the resistance of acute myelocytic
leukemia cells to therapy. Nat Commun. 10:38122019. View Article : Google Scholar
|
|
164
|
Bossis G, Sarry JE, Kifagi C, Ristic M,
Saland E, Vergez F, Salem T, Boutzen H, Baik H, Brockly F, et al:
The ROS/SUMO axis contributes to the response of acute myeloid
leukemia cells to chemotherapeutic drugs. Cell Rep. 7:1815–1823.
2014. View Article : Google Scholar
|
|
165
|
Golub TR, Barker GF, Bohlander SK, Hiebert
SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD and
Gilliland DG: Fusion of the TEL gene on 12p13 to the AML1 gene on
21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA.
92:4917–4921. 1995. View Article : Google Scholar
|
|
166
|
Chakrabarti SR, Sood R, Nandi S and
Nucifora G: Posttranslational modification of TEL and TEL/AML1 by
SUMO-1 and cell-cycle-dependent assembly into nuclear bodies. Proc
Natl Acad Sci USA. 97:13281–13285. 2000. View Article : Google Scholar
|
|
167
|
Hanson CA, Wood LD and Hiebert SW:
Cellular stress triggers TEL nuclear export via two genetically
separable pathways. J Cell Biochem. 104:488–498. 2008. View Article : Google Scholar
|
|
168
|
de Thé H, Lavau C, Marchio A, Chomienne C,
Degos L and Dejean A: The PML-RAR alpha fusion mRNA generated by
the t(15;17) translocation in acute promyelocytic leukemia encodes
a functionally altered RAR. Cell. 66:675–684. 1991. View Article : Google Scholar
|
|
169
|
Jeanne M, Lallemand-Breitenbach V, Ferhi
O, Koken M, Le Bras M, Duffort S, Peres L, Berthier C, Soilihi H,
Raught B and de Thé H: PML/RARA oxidation and arsenic binding
initiate the antileukemia response of As2O3. Cancer Cell. 18:88–98.
2010. View Article : Google Scholar
|
|
170
|
Ablain J, Rice K, Soilihi H, de Reynies A,
Minucci S and de Thé H: Activation of a promyelocytic
leukemia-tumor protein 53 axis underlies acute promyelocytic
leukemia cure. Nat Med. 20:167–174. 2014. View Article : Google Scholar
|
|
171
|
Tatham MH, Geoffroy MC, Shen L,
Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ and Hay RT:
RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for
arsenic-induced PML degradation. Nat Cell Biol. 10:538–546. 2008.
View Article : Google Scholar
|
|
172
|
Brackett CM and Blagg BS: Current status
of SUMOylation inhibitors. Curr Med Chem. 28:3892–3912. 2021.
View Article : Google Scholar
|
|
173
|
Yang Y, Xia Z, Wang X, Zhao X, Sheng Z, Ye
Y, He G, Zhou L, Zhu H, Xu N and Liang S: Small-molecule inhibitors
targeting protein SUMOylation as novel anticancer compounds. Mol
Pharmacol. 94:885–894. 2018. View Article : Google Scholar
|
|
174
|
Fukuda I, Ito A, Uramoto M, Saitoh H,
Kawasaki H, Osada H and Yoshida M: Kerriamycin B inhibits protein
SUMOylation. J Antibiot (Tokyo). 62:221–224. 2009. View Article : Google Scholar
|
|
175
|
Fukuda I, Ito A, Hirai G, Nishimura S,
Kawasaki H, Saitoh H, Kimura K, Sodeoka M and Yoshida M: Ginkgolic
acid inhibits protein SUMOylation by blocking formation of the
E1-SUMO intermediate. Chem Biol. 16:133–140. 2009. View Article : Google Scholar
|
|
176
|
Hirohama M, Kumar A, Fukuda I, Matsuoka S,
Igarashi Y, Saitoh H, Takagi M, Shin-ya K, Honda K, Kondoh Y, et
al: Spectomycin B1 as a novel SUMOylation inhibitor that directly
binds to SUMO E2. ACS Chem Biol. 8:2635–2642. 2013. View Article : Google Scholar
|
|
177
|
Kayser S, Schlenk RF and Platzbecker U:
Management of patients with acute promyelocytic leukemia. Leukemia.
32:1277–1294. 2018. View Article : Google Scholar
|
|
178
|
He X, Riceberg J, Soucy T, Koenig E,
Minissale J, Gallery M, Bernard H, Yang X, Liao H, Rabino C, et al:
Probing the roles of SUMOylation in cancer cell biology by using a
selective SAE inhibitor. Nat Chem Biol. 13:1164–1171. 2017.
View Article : Google Scholar
|
|
179
|
Langston SP, Grossman S, England D, Afroze
R, Bence N, Bowman D, Bump N, Chau R, Chuang BC, Claiborne C, et
al: Discovery of TAK-981, a first-in-class inhibitor of
SUMO-activating enzyme for the treatment of cancer. J Med Chem.
64:2501–2520. 2021. View Article : Google Scholar
|
|
180
|
Lv Z, Yuan L, Atkison JH, Williams KM,
Vega R, Sessions EH, Divlianska DB, Davies C, Chen Y and Olsen SK:
Molecular mechanism of a covalent allosteric inhibitor of SUMO E1
activating enzyme. Nat Commun. 9:51452018. View Article : Google Scholar
|
|
181
|
Li YJ, Du L, Wang J, Vega R, Lee TD, Miao
Y, Aldana-Masangkay G, Samuels ER, Li B, Ouyang SX, et al:
Allosteric inhibition of ubiquitin-like modifications by a class of
inhibitor of SUMO-activating enzyme. Cell Chem Biol. 26:278–288.e6.
2019. View Article : Google Scholar
|
|
182
|
Takemoto M, Kawamura Y, Hirohama M,
Yamaguchi Y, Handa H, Saitoh H, Nakao Y, Kawada M, Khalid K,
Koshino H, et al: Inhibition of protein SUMOylation by davidiin, an
ellagitannin from Davidia involucrata. J Antibiot (Tokyo).
67:335–338. 2014. View Article : Google Scholar
|
|
183
|
Suzawa M, Miranda DA, Ramos KA, Ang KK,
Faivre EJ, Wilson CG, Caboni L, Arkin MR, Kim YS, Fletterick RJ, et
al: A gene-expression screen identifies a non-toxic sumoylation
inhibitor that mimics SUMO-less human LRH-1 in liver. Elife.
4:e090032015. View Article : Google Scholar
|
|
184
|
Lu X, Olsen SK, Capili AD, Cisar JS, Lima
CD and Tan DS: Designed semisynthetic protein inhibitors of Ub/Ubl
E1 activating enzymes. J Am Chem Soc. 132:1748–1749. 2010.
View Article : Google Scholar
|
|
185
|
Berger AJ, Friedlander S, Ghasemi O,
Grossman S and Huszar D: Abstract 3079: Pharmacodynamic evaluation
of the novel SUMOylation inhibitor TAK-981 in a mouse tumor model.
In: Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019;
Atlanta, GA. pp. 792019
|
|
186
|
Kumar A, Ito A, Hirohama M, Yoshida M and
Zhang KY: Identification of sumoylation activating enzyme 1
inhibitors by structure-based virtual screening. J Chem Inf Model.
53:809–820. 2013. View Article : Google Scholar
|
|
187
|
Biederstädt A, Hassan Z, Schneeweis C,
Schick M, Schneider L, Muckenhuber A, Hong Y, Siegers G, Nilsson L,
Wirth M, et al: SUMO pathway inhibition targets an aggressive
pancreatic cancer subtype. Gut. 69:1472–1482. 2020. View Article : Google Scholar
|
|
188
|
Kumar A, Ito A, Hirohama M, Yoshida M and
Zhang KY: Identification of new SUMO activating enzyme 1 inhibitors
using virtual screening and scaffold hopping. Bioorg Med Chem Lett.
26:1218–1223. 2016. View Article : Google Scholar
|
|
189
|
Brandt M, Szewczuk LM, Zhang H, Hong X,
McCormick PM, Lewis TS, Graham TI, Hung ST, Harper-Jones AD,
Kerrigan JJ, et al: Development of a high-throughput screen to
detect inhibitors of TRPS1 sumoylation. Assay Drug Dev Technol.
11:308–325. 2013. View Article : Google Scholar
|
|
190
|
Zlotkowski K, Hewitt WM, Sinniah RS,
Tropea JE, Needle D, Lountos GT, Barchi JJ Jr, Waugh DS and
Schneekloth JS Jr: A Small-molecule microarray approach for the
identification of E2 enzyme inhibitors in ubiquitin-like
conjugation pathways. SLAS Discov. 22:760–766. 2017.
|
|
191
|
Wiechmann S, Gärtner A, Kniss A, Stengl A,
Behrends C, Rogov VV, Rodriguez MS, Dötsch V, Müller S and Ernst A:
Site-specific inhibition of the small ubiquitin-like modifier
(SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain
formation. J Biol Chem. 292:15340–15351. 2017. View Article : Google Scholar
|
|
192
|
Kim YS, Nagy K, Keyser S and Schneekloth
JS Jr: An electrophoretic mobility shift assay identifies a
mechanistically unique inhibitor of protein sumoylation. Chem Biol.
20:604–613. 2013. View Article : Google Scholar
|
|
193
|
Ambaye N, Chen CH, Khanna S, Li YJ and
Chen Y: Streptonigrin inhibits SENP1 and reduces the protein level
of hypoxia-inducible factor 1α (HIF1α) in cells. Biochemistry.
57:1807–1813. 2018. View Article : Google Scholar
|
|
194
|
Chen Y, Wen D, Huang Z, Huang M, Luo Y,
Liu B, Lu H, Wu Y, Peng Y and Zhang J:
2-(4-Chlorophenyl)-2-oxoethyl 4-benzamidobenzoate derivatives, a
novel class of SENP1 inhibitors: Virtual screening, synthesis and
biological evaluation. Bioorg Med Chem Lett. 22:6867–6870. 2012.
View Article : Google Scholar
|
|
195
|
Qiao Z, Wang W, Wang L, Wen D, Zhao Y,
Wang Q, Meng Q, Chen G, Wu Y and Zhou H: Design, synthesis, and
biological evaluation of benzodiazepine-based SUMO-specific
protease 1 inhibitors. Bioorg Med Chem Lett. 21:6389–6392. 2011.
View Article : Google Scholar
|
|
196
|
Uno M, Koma Y, Ban HS and Nakamura H:
Discovery of 1-[4-(N-benzylamino)phenyl]-3-phenylurea derivatives
as non-peptidic selective SUMO-sentrin specific protease (SENP)1
inhibitors. Bioorg Med Chem Lett. 22:5169–5173. 2012. View Article : Google Scholar
|
|
197
|
Xie W, Wang Z, Zhang J, Wang L, Zhao Y and
Zhou H: Development and evaluation of a highly reliable assay for
SUMO-specific protease inhibitors. Bioorg Med Chem Lett.
26:2124–2128. 2016. View Article : Google Scholar
|
|
198
|
Lindenmann U, Brand M, Gall F, Frasson D,
Hunziker L, Kroslakova I, Sievers M and Riedl R: Discovery of a
class of potent and selective Non-competitive Sentrin-Specific
protease 1 inhibitors. ChemMedChem. 15:675–679. 2020. View Article : Google Scholar
|
|
199
|
Zhao Y, Wang Z, Zhang J and Zhou H:
Identification of SENP1 inhibitors through in silico screening and
rational drug design. Eur J Med Chem. 122:178–184. 2016. View Article : Google Scholar
|
|
200
|
Wu J, Lei H, Zhang J, Chen X, Tang C, Wang
W, Xu H, Xiao W, Gu W and Wu Y: Momordin Ic, a new natural SENP1
inhibitor, inhibits prostate cancer cell proliferation. Oncotarget.
7:58995–59005. 2016. View Article : Google Scholar
|
|
201
|
Huang W, He T, Chai C, Yang Y, Zheng Y,
Zhou P, Qiao X, Zhang B, Liu Z, Wang J, et al: Triptolide inhibits
the proliferation of prostate cancer cells and down-regulates
SUMO-specific protease 1 expression. PLoS One. 7:e376932012.
View Article : Google Scholar
|
|
202
|
Bernstock JD, Ye D, Smith JA, Lee YJ,
Gessler FA, Yasgar A, Kouznetsova J, Jadhav A, Wang Z, Pluchino S,
et al: Quantitative high-throughput screening identifies
cytoprotective molecules that enhance SUMO conjugation via the
inhibition of SUMO-specific protease (SENP)2. FASEB J.
32:1677–1691. 2018. View Article : Google Scholar
|
|
203
|
Kumar A, Ito A, Takemoto M, Yoshida M and
Zhang KY: Identification of 1,2,5-oxadiazoles as a new class of
SENP2 inhibitors using structure based virtual screening. J Chem
Inf Model. 54:870–880. 2014. View Article : Google Scholar
|
|
204
|
Boggio R, Colombo R, Hay RT, Draetta GF
and Chiocca S: A mechanism for inhibiting the SUMO pathway. Mol
Cell. 16:549–561. 2004. View Article : Google Scholar
|
|
205
|
Liang Z, Chan HYE, Lee MM and Chan MK: A
SUMO1-derived peptide targeting SUMO-interacting motif inhibits
α-Synuclein aggregation. Cell Chem Biol. 28:180–190.e6. 2021.
View Article : Google Scholar
|
|
206
|
Sakamoto KM, Kim KB, Kumagai A, Mercurio
F, Crews CM and Deshaies RJ: Protacs: Chimeric molecules that
target proteins to the Skp1-Cullin-F box complex for ubiquitination
and degradation. Proc Natl Acad Sci USA. 98:8554–8559. 2001.
View Article : Google Scholar
|
|
207
|
Jakobs A, Koehnke J, Himstedt F, Funk M,
Korn B, Gaestel M and Niedenthal R: Ubc9 fusion-directed
SUMOylation (UFDS): A method to analyze function of protein
SUMOylation. Nat Methods. 4:245–250. 2007. View Article : Google Scholar
|
|
208
|
Chen X, Zaro JL and Shen WC: Fusion
protein linkers: Property, design and functionality. Adv Drug Deliv
Rev. 65:1357–1369. 2013. View Article : Google Scholar
|
